Published in J Cancer on April 12, 2012
On the origin of cancer metastasis. Crit Rev Oncog (2013) 0.97
Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med (2014) 0.92
An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors. ISRN Pharmacol (2012) 0.80
SOX2 and OCT4 mRNA-expressing cells, detected by molecular beacons, localize to the center of neurospheres during differentiation. PLoS One (2013) 0.78
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia (2002) 5.81
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 4.29
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res (2008) 3.22
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res (2006) 2.68
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J (2010) 2.01
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 2.00
Retracted Marker-independent identification of glioma-initiating cells. Nat Methods (2010) 1.84
Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci (2006) 1.74
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Pten signaling in gliomas. Neuro Oncol (2002) 1.62
Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett (2009) 1.62
Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol (2007) 1.58
Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res (2008) 1.58
CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol (2008) 1.56
Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia (2009) 1.39
Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun (2011) 1.39
Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res (2010) 1.24
Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res (2010) 1.24
Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am (2010) 1.22
The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology (2011) 1.16
High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev (2009) 1.12
Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol (2008) 1.11
Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res (2008) 1.04
A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol (2010) 1.03
Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. Oncol Rep (2011) 0.96
Ganglioside composition of an experimental mouse brain tumor. Cancer Res (1987) 0.95
Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link? Neuropharmacology (2010) 0.93
Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. Histol Histopathol (2007) 0.89
Embryonic stem cell-derived astrocytes expressing drug-inducible transgenes: differentiation and transplantion into the mouse brain. J Neurosurg (2005) 0.86
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene (2005) 2.58
Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res (2008) 2.45
Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci U S A (2006) 2.38
Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene (2005) 2.34
Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem (2008) 2.08
Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells. J Neurosurg (2007) 1.63
In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas. Neuro Oncol (2008) 1.62
BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. Cancer Res (2006) 1.58
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56
Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology (2011) 1.54
Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene (2005) 1.49
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther (2008) 1.48
Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. J Neurosurg (2003) 1.41
Astrocyte elevated gene-1: far more than just a gene regulated in astrocytes. Cancer Res (2009) 1.40
MacroH2A histone variants act as a barrier upon reprogramming towards pluripotency. Nat Commun (2013) 1.39
Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology. Pharmacol Ther (2011) 1.37
mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer Res (2005) 1.35
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets (2012) 1.33
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model. Hepatology (2012) 1.32
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30
Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity. Cancer Res (2011) 1.25
Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci U S A (2008) 1.22
Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2010) 1.20
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg (2003) 1.20
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther (2008) 1.18
Efficient differentiation of human embryonic and induced pluripotent stem cells into functional astrocytes. Stem Cells Dev (2011) 1.17
Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci U S A (2005) 1.17
mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB. Cancer Res (2007) 1.15
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Mol Cancer Ther (2008) 1.11
Defining the domains of human polynucleotide phosphorylase (hPNPaseOLD-35) mediating cellular senescence. Mol Cell Biol (2005) 1.09
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther (2009) 1.08
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy (2008) 1.06
Enterovirus 2Apro targets MDA5 and MAVS in infected cells. J Virol (2014) 1.06
Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One (2013) 1.03
MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Res (2012) 1.03
Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci (2011) 1.03
Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation. Cancer Res (2004) 1.01
Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression. J Cell Physiol (2007) 1.00
Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy? Expert Opin Biol Ther (2007) 1.00
Novel role of MDA-9/syntenin in regulating urothelial cell proliferation by modulating EGFR signaling. Clin Cancer Res (2013) 0.99
The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther (2010) 0.98
No circulating cytomegalovirus in five patients with glioblastoma multiforme. Anticancer Res (2011) 0.96
Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol (2011) 0.96
Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9). J Biol Chem (2011) 0.95
MDA-7/IL-24: multifunctional cancer killing cytokine. Adv Exp Med Biol (2014) 0.93
Internalization and dephosphorylation of connexin43 in hypertrophied right ventricles of rats with pulmonary hypertension. Circ J (2007) 0.92
Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC). Mol Ther (2013) 0.92
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs (2010) 0.91
American College of Radiology appropriateness criteria on multiple brain metastases. Int J Radiat Oncol Biol Phys (2009) 0.91
Potential molecular mechanism for rodent tumorigenesis: mutational generation of Progression Elevated Gene-3 (PEG-3). Oncogene (2005) 0.90
Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. J Cell Physiol (2008) 0.90
Targeting tumor invasion: the roles of MDA-9/Syntenin. Expert Opin Ther Targets (2014) 0.89
Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer Res (2013) 0.89
MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro Oncol (2013) 0.88
Embryonic stem cell-derived astrocytes: a novel gene therapy vector for brain tumors. Neurosurg Focus (2005) 0.86
Future approaches for the therapy of malignant glioma: targeting genes mediating invasion. Future Oncol (2012) 0.85
Evaluation of factors predicting accurate resection of high-grade gliomas by using frameless image-guided stereotactic guidance. Neurosurg Focus (2003) 0.84
ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol (2010) 0.84
Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther (2002) 0.83
Innovative approaches for enhancing cancer gene therapy. Discov Med (2013) 0.83
Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas? Neuro Oncol (2011) 0.82
Identification of genes potentially regulated by human polynucleotide phosphorylase (hPNPase old-35) using melanoma as a model. PLoS One (2013) 0.81
Radiosurgery for high-grade glioma. Surg Neurol Int (2012) 0.81
Correlation of factors predicting intraoperative brain shift with successful resection of malignant brain tumors using image-guided techniques. Surg Neurol (2005) 0.80
Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells. J Neurooncol (2014) 0.79
"Footprint-free" human induced pluripotent stem cell-derived astrocytes for in vivo cell-based therapy. Stem Cells Dev (2014) 0.78
Attrition rates in neurosurgery residency: analysis of 1361 consecutive residents matched from 1990 to 1999. J Neurosurg (2014) 0.78
Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. Anticancer Agents Med Chem (2012) 0.77
Expression patterns of MDA-9/syntenin during development of the mouse embryo. J Mol Histol (2012) 0.77
Human polynucleotide phosphorylase (hPNPaseold-35): should I eat you or not--that is the question? Adv Cancer Res (2013) 0.77
Down-regulation of telomerase activity in malignant glioma cells by p27KIP1. Int J Oncol (2003) 0.76
Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials. Expert Opin Investig Drugs (2014) 0.76
Noninvasive approaches for detecting and monitoring bladder cancer. Expert Rev Anticancer Ther (2014) 0.76
Analysis of global changes in gene expression induced by human polynucleotide phosphorylase (hPNPase(old-35)). J Cell Physiol (2014) 0.76
Editor's Note: /Syntenin: A Positive Regulator of Melanoma Metastasis. Cancer Res (2019) 0.75
Scalp nerve blockade reduces pain after headframe placement in radiosurgery: a double blind, randomized clinical trial. Middle East J Anaesthesiol (2013) 0.75